These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 2503409)

  • 21. [Production of HBV surface antigen-specific target cell].
    Zhou Z; Zhang D; Ren H
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1999 Sep; 13(3):231-4. PubMed ID: 12569752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
    Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
    Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chromosome aberration and carcinogenicity of CHO dhfr- cells transformed by plasmid containing S+ and Pre S1 of fusion gene of hepatitis B virus].
    Tian SF; Ruan WQ; Wang XP; Zhang LL; Yang FR; Zong F; Ruan L
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Sep; 15(3):208-11. PubMed ID: 11986685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Biosynthesis of recombinant human hepatitis B M-HBsAg in silkworm larvae].
    Likhoradova OA; Bachurina EIu; Azimova ShS
    Mol Biol (Mosk); 2004; 38(4):717-22. PubMed ID: 15456144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uncorking the biomanufacturing bottleneck.
    Dove A
    Nat Biotechnol; 2002 Aug; 20(8):777-9. PubMed ID: 12148000
    [No Abstract]   [Full Text] [Related]  

  • 26. [Isolation of a recombinant vaccinia virus based on the LIVP strain inducing the surface antigen of the hepatitis B virus].
    Al'tshteĭn AD; Zakharova LG; Loparev VN; Pashvykina GV; Gorodetskiĭ SI
    Dokl Akad Nauk SSSR; 1985; 285(3):696-9. PubMed ID: 4092585
    [No Abstract]   [Full Text] [Related]  

  • 27. Production and analysis of proteins by recombinant DNA technology.
    Pestka S
    Bioprocess Technol; 1990; 7():235-65. PubMed ID: 1366823
    [No Abstract]   [Full Text] [Related]  

  • 28. Apparent heterogeneity of recombinant interferon gamma receptors produced in prokaryotic and eukaryotic expression systems.
    Fountoulakis M
    J Chem Technol Biotechnol; 1996 Feb; 65(2):123-30. PubMed ID: 8672294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles.
    Lee IH; Kim CH; Ryu WS
    J Med Virol; 1996 Oct; 50(2):145-51. PubMed ID: 8915880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of HBsAg and preS2-S protein in different yeast based system: a comparative analysis.
    Hadiji-Abbes N; Borchani-Chabchoub I; Triki H; Ellouz R; Gargouri A; Mokdad-Gargouri R
    Protein Expr Purif; 2009 Aug; 66(2):131-7. PubMed ID: 19303931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a hepatitis B vaccine from transformed yeast cells.
    Pêtre J; Van Wijnendaele F; De Neys B; Conrath K; Van Opstal O; Hauser P; Rutgers T; Cabezon T; Capiau C; Harford N
    Postgrad Med J; 1987; 63 Suppl 2():73-81. PubMed ID: 3317362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of complex B cell epitopes on woodchuck hepatitis virus surface antigens by using plasmids encoding chimeric proteins and DNA immunization.
    Zheng X; Schirmbeck R; Hilken G; Waters JA; Yang D; Reimann J; Roggendorf M; Lu M
    Virology; 2002 Mar; 294(2):342-53. PubMed ID: 12009876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of a new hydrophobic interaction chromatography absorbent and its application to the purification of recombinant hepatitis B surface antigen].
    Wang YM; Bi JX; Zhao L; Zhou WB; Li Y; Huang YD; Zhang Y; Lin H; Su ZG
    Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):278-84. PubMed ID: 16607957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylotrophic yeast hansenula polymorpha as production organism for recombinant pharmaceuticals.
    Gellissen G; Melber K
    Arzneimittelforschung; 1996 Sep; 46(9):943-8. PubMed ID: 8876947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.
    Wyatt LS; Moss B; Rozenblatt S
    Virology; 1995 Jun; 210(1):202-5. PubMed ID: 7793072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fermentation processes for prokaryotic cells.
    Muth WL
    Bioprocess Technol; 1991; 13():155-65. PubMed ID: 1367132
    [No Abstract]   [Full Text] [Related]  

  • 37. Restriction of vaccinia virus replication in CHO cells occurs at the stage of viral intermediate protein synthesis.
    Ramsey-Ewing A; Moss B
    Virology; 1995 Feb; 206(2):984-93. PubMed ID: 7856109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Influence of the mutants of hepatitis B surface antigen on the cell immunity].
    Bai Y; Xia GL; Guo Y; Cong Y; Jia ZY; Guo MZ; Zhao HL; Zhan MY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Jun; 19(2):124-7. PubMed ID: 16027776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Vaccinia's innate ability to introduce DNA into mammalian cells for production of recombinant proteins.
    Jester BC; Drillien R; Ruff M; Florentz C
    J Biotechnol; 2011 Dec; 156(3):211-3. PubMed ID: 21945587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of heat shock proteins (HSPs) in CHO cells for extended culture viability and improved recombinant protein production.
    Lee YY; Wong KT; Tan J; Toh PC; Mao Y; Brusic V; Yap MG
    J Biotechnol; 2009 Aug; 143(1):34-43. PubMed ID: 19527755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.